Biologics Safety Testing Market Size, Share & Trends Analysis By Product & Service, By Application, By Test Type, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Biologics Safety Testing Market Size, Share & Trends Analysis By Product & Service, By Application, By Test Type, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

The global Biologics Safety Testing Market is projected to be worth USD 8.56 billion by 2030.

According to SPER Market Research, the Biologics Safety Testing Market is estimated to reach USD 8.56 billion by 2030 with a CAGR of 10.8%.

The expansion of the biologics and biosimilars markets, increasing concerns over cell culture contamination, and rising biopharmaceuticals research & development activities and investments, emerging markets, and growing biopharmaceutical outsourcing; are the key driver for the escalation of the market.

Impact of COVID-19 on the Biologics Safety Testing Market

To provide biologics safety testing for developing safety test kits, manufacturing of vaccines testing to treat and target the infection. Pharmaceutical and biopharmaceutical companies and the biologics safety testing market have taken steps toward research in biologics safety testing.

Scope of the report:

Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030

Segments covered By Product, By Application, By End-User, By Region

Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered

Agilent Technologies, Inc., Almac Group, Associates of Cape Cod, Inc. BioMérieux SA, Bio-Rad Laboratories, Inc., Charles River Laboratories, Inc., Lonza, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fujifilm Wako Pure Chemical Corporation, Maravai Lifesciences, Merck KGaA, Microcoat Biotechnologie GmbH, Nelson Laboratories, LLC, Pacific BioLabs, PromoCell GmbH, Sartorius AG, SGS SA, Thermo Fisher Scientific, Inc., WuXi AppTec.

Driver: expansion in the biosimilars and biologics markets

Heavy investments in the development of biologics and biosimilars by big companies. Growth in the biosimilars and biologics markets, Growing concerns over cell culture contamination, rising biopharmaceuticals R&D activities and investments; are the key factors, which drive the market expansion.

Opportunity: Emerging markets offer profitable opportunities

Emerging markets offer rewarding opportunities, and growing biopharmaceutical outsourcing; will provide enormous opportunities in the Biologics Safety Testing Market.

Challenges: lack of skilled professionals

Lack of skilled personnel to handle the advanced technologies and the development of new and improved safety testing.

Global Biologics Safety Testing Market, By Product & Service:

Based on the Product & Service, Global Biologics Safety Testing Market is segmented as; Consumables, Instrument, and Services.

Global Biologics Safety Testing Market, By Application:

Based on the Application, Global Biologics Safety Testing Market is segmented as; Blood and Blood Products Manufacturing, Cellular & Gene Therapy Products Manufacturing, Monoclonal Antibodies Manufacturing, and Vaccine Manufacturing.

Global Biologics Safety Testing Market, By Test Type:

Based on the Test Type, Global Biologics Safety Testing Market is segmented into; Bioburden Tests, Endotoxin tests, Mycoplasma Tests, Residual Host-cell Proteins & DNA Detection Tests, Sterility tests, and Virus safety tests.

Global Biologics Safety Testing Market, By Region:

North America dominates the biggest share of the market; this is due to the increasing academic and government investments, quick expansion in the biopharmaceutical industry, growing demand for high-quality research tools for data reproducibility, and growing alertness among consumers about product safety.